B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals

Study of the B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals With Beta-thalassemia Major

Status

UNKNOWN

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01846923

Enrollment

Registered

2013-05-06

Start date

2010-10-31

Completion date

Unknown

Last updated

2013-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asplenia, β-thalassemia Major

Brief summary

The purpose of this study is to determine whether one dose of the 13-valent pneumococcal conjugate vaccine (PCV13) induces immunological memory in asplenic adults and whether previously administered immunizations with the 23-valent polysaccharide pneumococcal vaccine influence the cellular immune response to PCV13 in this group.

Interventions

BIOLOGICALPCV13

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

* Asplenia * β-thalassemia major * older than 18 years

Exclusion criteria

* no previously recorded allergy to PCV * no intravenous immunoglobulin (IVIG) given within the previous 6 months * no other vaccine given within the previous 6 months

Design outcomes

Primary

Measure	Time frame
immunoglobulin G (IgG) B memory cell response one month post vaccination (measured by ELISpot)	One month post-PCV13
immunoglobulin M (IgM) B memory cell response one month post vaccination (measured by ELISpot)	one month post PCV13

Secondary

Measure	Time frame
Maintenance of B memory cells three years after PCV13 vaccination	three years after study vaccination

Countries

Greece

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 8, 2026